Combined treatment with avelumab and axitinib for advanced type B3 thymoma and thymic carcinoma shows promise as second-line therapy after standard treatment.  |  Medicine in 2 Minutes

Combined treatment with avelumab and axitinib for advanced type B3 thymoma and thymic carcinoma shows promise as second-line therapy after standard treatment. | Medicine in 2 Minutes

1. Patients who had never received anti-angiogenesis therapy had longer progression-free survival 2. Adverse effects of the combination of avelumab and axitinib are mild and include abdominal pain, diarrhea, nausea and vomiting. Level of evidence assessment: 2 (Good) Summary of the study: Type B3 thymoma and thymic carcinoma are aggressive tumors with poor survival outcomes …

Combined treatment with avelumab and axitinib for advanced type B3 thymoma and thymic carcinoma shows promise as second-line therapy after standard treatment. | Medicine in 2 Minutes Read More »